Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to compare the effectiveness of testosterone,estradiol and a combined treatment with estrogens/progestagens prior to IVF-ICSI in previously diagnosed low responder patients.


Clinical Trial Description

During controlled ovarian hyperstimulation (COH), most of the early antral follicles are required to grow coordinately. Marked follicular size discrepancies during COH imply that an important number of follicles undergo unsatisfactory maturation. It has been proved that follicular priming with estradiol during the luteal phase of the cycle prior to COH or testosterone treatment during the early follicular phase of the COH cycle may increase the amount of oocytes and embryos retrieved. Nevertheless there are no prospective studies comparing such approaches. The present study consist of two phases:

The present study consists of two different phases:

- Phase I: (Non randomized) Identification of confirmed low responder patients. Potential low responder patients will be subjected to an standardized ovarian hyperstimulation protocol

- Phase II: (Randomized) those patients, once confirmed as low responders, will be offered the opportunity to enter the interventional part of the study, being randomized to three different treatment groups: estradiol, testosterone or combined progestagens and estrogens prior to the IVF-ICSI cycle. The previous cycle (phase I) will be used as a self-control for each patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01310647
Study type Interventional
Source Instituto de Investigacion Sanitaria La Fe
Contact
Status Completed
Phase Phase 2
Start date June 2011
Completion date February 2014

See also
  Status Clinical Trial Phase
Completed NCT00210249 - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Completed NCT01460979 - Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Phase 2
Terminated NCT01016054 - A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer Phase 1
Completed NCT00816764 - A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer Phase 1
Completed NCT00050414 - A Study of Trabectedin in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT02973750 - Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05617755 - AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer Phase 1
Completed NCT01462890 - Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Phase 3
Completed NCT01832116 - 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients Phase 1
Not yet recruiting NCT04807166 - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Phase 2
Recruiting NCT04189406 - Turner Syndrome Minipuberty Study
Not yet recruiting NCT04579575 - Added Value of O-RADS in Evaluation of Ovarian Lesions
Completed NCT04209881 - Ovarian Reserve and Ankylosing Spondylitis
Not yet recruiting NCT05048654 - A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy
Completed NCT03593681 - Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Terminated NCT01292733 - Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer Phase 0